Öppna denna publikation i ny flik eller fönster >>2002 (Engelska)Ingår i: Survey of ophthalmology, ISSN 0039-6257, E-ISSN 1879-3304, Vol. 47, nr 4S1, s. 77-89Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
OBJECTIVE:
To study the intraocular pressure (IOP) reduction of latanoprost or timolol in a heterogeneous global population.
METHODS:
A total of 1,389 glaucoma or ocular hypertensive patients treated with 0.005% latanoprost once daily (n = 737) or 0.5% timolol twice daily (n = 652) from eight clinical trials were included. After 3-6 months of treatment, the IOP was analyzed with use of analysis of covariance.
RESULTS:
Latanoprost or timolol gave statistically significant mean diurnal IOP reduction in the African-American, Asian, Caucasian, and Mexican patients, latanoprost with 7.9 mm Hg and timolol with 6.4 mm Hg. The Asian and Mexican patients showed a larger difference in mean diurnal IOP reduction with use of the two drugs (range 1.8-3.1 mm Hg) than the European and U.S. patients (range 0.6-1.7 mm Hg, p = 0.030). Latanoprost produced similar mean diurnal IOP reduction in patients with and without previous glaucoma treatment other than prostaglandins.
CONCLUSION:
Latanoprost or timolol statistically significantly reduced the mean diurnal IOP in a heterogenous global population in eight clinical trials. The degree of reduction appeared to be clinically useful. The greatest difference in the mean diurnal IOP-lowering effect of latanoprost or timolol was observed in Mexican and Asian clinical trials.
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
urn:nbn:se:uu:diva-90323 (URN)10.1016/S0039-6257(02)00310-7, (DOI)12204703 (PubMedID)
2003-04-072003-04-072017-12-14Bibliografiskt granskad